EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?

Jérôme Avouac, Marc Scherlinger, Club for Innovative Immunotherapies in Immune-Mediated Inflammatory Diseases (C3I)

BioDrugs · 2025

DOI: 10.1007/s40259-024-00692-z ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioDrugs, 2025. Verfasst von Jérôme Avouac und 2 weiteren Autor:innen. Beteiligte Einrichtung: Service de Rhumatologie, Hôpital Cochin, AP-HP, CUP, Université Paris Descartes, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France. jerome.avoua…. Hauptthemen laut MEDLINE: Rheumatic Diseases, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T-cell therapy, initially successful in treating hematological malignancies, is emerging as a potential treatment for autoimmune diseases, including rheumatic conditions. CAR T cells, engineered to target and eliminate autoreactive B cells, offer a novel approach to managing diseases like systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myopathies, where B cells play a pivotal role in disease pathology. Early case reports have demonstrated promising results, with patients achieving significant disease remission, normalization of serological markers, and the ability to discontinue traditional immunosuppressive therapies, which supported the initiation of several clinical trials. However, the application of CAR T-cell therapy in chronic inflammatory rheumatic disorders poses unique challenges, including patient heterogeneity, the risk of adverse effects such as cytokine release syndrome, and the high costs associated with the therapy. Despite these challenges, the potential for CAR T cells to provide long-term remission or even a cure in refractory autoimmune diseases is significant. Ongoing research aims to optimize CAR T-cell constructs and improve safety profiles, paving the way for broader application in rheumatic diseases. If these challenges can be addressed, CAR T-cell therapy could revolutionize the treatment landscape for chronic inflammatory rheumatic disorders, offering new hope for patients with severe, treatment-resistant conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rheumatic DiseasesReceptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesHumansAnimals

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Service de Rhumatologie, Hôpital Cochin, AP-HP, CUP, Université Paris Descartes, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France. jerome.avouac@aphp.fr.
  • INSERM U1016 and UMR8104, Institut Cochin, 75014, Paris, France. jerome.avouac@aphp.fr.
  • Rheumatology Department, Strasbourg University Hospital, 1 Avenue Molière, 67000, Strasbourg, France.
  • UMR_S INSERM 1109, Immunorhumatologie moléculaire, 1 place de l'hôpital, 67000, Strasbourg, France.

Zitieren

APA

Avouac, J., Scherlinger, M., & Club for Innovative Immunotherapies in Immune-Mediated Inflammatory Diseases (C3I) (2025). CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?. BioDrugs. https://doi.org/10.1007/s40259-024-00692-z

Vancouver

Avouac J, Scherlinger M, Club for Innovative Immunotherapies in Immune-Mediated Inflammatory Diseases (C3I). CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?. BioDrugs. 2025. doi:10.1007/s40259-024-00692-z

BibTeX
@article{Avouac2025,
  author = {Avouac, Jérôme and Scherlinger, Marc and Club for Innovative Immunotherapies in Immune-Mediated Inflammatory Diseases (C3I), Club for Innovative Immunotherapies in Immune-Mediated Inflammatory Diseases (C3I)},
  title = {CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?},
  journal = {BioDrugs},
  year = {2025},
  doi = {10.1007/s40259-024-00692-z}
}
Kostenlos starten →